



INSIDE THIS ISSUE

- Benefit Drug List Update - Amifostine, dexrazoxane, temozolomide; New programs: Breast (BRAJTAM), CNS (CNCCV, CNTEMOZ, CNIME), GI (GIIRFUFA), Lung (LUDOC), and Pediatrics (Aldesleukin, Amifostine, Dexrazoxane, Temozolomide, Topotecan, Trastuzumab)
- Protocol Update - BMT & Leukemia: CMLIFNCYT; Central Nervous System: CNIME, CNTEMOZ; Gastrointestinal: GIIRFUFA; Gyne: GOCXADV, GOTDLR; Lung: LUDOC; Lymphoma & Myeloma: LYACOP6, LYACOP12, LYCOPA, MYMP
- Pre-Printed Order Update – GOCXADV, LYHDMTX, LYODBEP, 2-day treatment model
- Drug Update – Amifostine, EMLA™, zoledronic acid

FAX request form and IN TOUCH phone list are provided if additional information is needed.

BENEFIT DRUG LIST UPDATE

The Provincial Systemic Therapy Program is pleased to announce that additional funds were obtained for new programs and to allow growth in existing programs. There are now 19,000 patients per year accessing cancer drugs in this province and the drug budget will be close to \$37 million this year.

The following new programs will be funded by the Provincial Systemic Therapy Program effective November 1, 2000:

Breast

- Adjuvant **tamoxifen** for ductal carcinoma in situ and minimally invasive breast cancer (protocol BRAJTAM).

Central Nervous System

- Adjuvant **cisplatin**, **lomustine** and **vincristine** for adult high-risk medulloblastoma or other primitive neuroectodermal tumour (protocol CNCCV).
- Second line **temozolomide** for recurrent gliomas (protocol CNTEMOZ).
- **Ifosfamide**, **Mesna** and **etoposide** for recurrent brain tumours (protocol CNIME).

Gastrointestinal

First line **irinotecan** plus **fluorouracil** and **leucovorin** for metastatic colorectal cancer (protocol GIIRFUFA).

Lung

- Second line **docetaxel** for nonsmall cell lung cancer (protocol LUDOC).

Pediatrics

- **Aldesleukin** (interleukin 2) for children with AML or myelodysplastic syndrome treated on the CCG 2961 study or its companion study
- **Amifostine** for children with high-risk germ cell tumours treated on the CCG P9749 study; hepatoblastoma treated on the CCG P9645 study; relapsed solid tumours treated with a bone marrow transplant or autologous peripheral stem cell re-infusion.
- **Dexrazoxane** for children with newly diagnosed, non-metastatic osteosarcoma treated on the CCG P9754 study
- **Temozolomide** for pediatric brain tumours
- **Topotecan** for children with relapsed solid tumours treated on the CCG 09713 study; relapsed leukemia treated on the CCG 09714 study; refractory meningeal malignancies treated on the CCG P9962 study
- **Trastuzumab** for pediatric osteogenic sarcoma

Aldesleukin, amifostine, dexrazoxane, docetaxel, irinotecan, temozolomide, topotecan, and trastuzumab are approved as Class II drugs on the benefit list. A Class II form must be completed and submitted to the Provincial Systemic Therapy Program before the drugs will be dispensed at a regional cancer centre or reimbursed to a community hospital.

Susan O'Reilly, MB, FRCPC
Provincial Systemic Program Leader

The current Benefit Drug List is available on the website <http://bccancer.com>

PROTOCOL UPDATE

Protocol codes for treatments requiring "Undesignated Indication" approval prior to use are prefixed with the letter **U**.

- **INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group, protocol code, indication, drugs, last revision date and version)
- **CMLIFNCYT** new: Cytarabine and interferon (Class II) for chronic myeloid leukemia.
- **CNIME** revised (undesignated indication approval no longer required): Ifosfamide, Mesna and etoposide for recurrent brain tumours.
- **CNTEMOZ** revised (undesignated indication approval no longer required): Temozolomide for recurrent gliomas.
- **GOCXADV** revised (dose modifications and support drugs clarified): Cisplatin and etoposide for advanced/recurrent non-small cell cervical cancer.
- **GIIRFUFA** revised (undesignated indication approval no longer required, dose modifications clarified): First line irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer.
- **GOTDLR** revised (tests clarified): Dactinomycin and methotrexate for low risk gestational trophoblastic cancer.
- **LUDOC** new: Docetaxel for 2nd line treatment of nonsmall cell lung cancer.

- **LYACOP6** deleted (replaced by LYCHOP)
- **LYACOP12** deleted (replaced by LYCHOP)
- **LYCOPA** deleted (replaced by LYCHOP)
- **MYMP** reformatted: Melphalan and prednisone for multiple myeloma.

PRE-PRINTED ORDER UPDATE

Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre (VCC) has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

GOCXADV revised: Treatment of advanced/recurrent non-small cell cancer of the cervix with cisplatin and etoposide.

LYHDMTX revised: Treatment of primary and leptomeningeal or recurrent intracerebral lymphoma with high dose methotrexate.

LYODBEP revised: Treatment of Hodgkin's disease in elderly patients with vincristine, doxorubicin, bleomycin, etoposide and prednisone.

Two-day Treatment Model

In October, the VCC preprinted orders were revised to accommodate the two-day treatment model (the patient sees the physician on the first day and receives treatment the next day). VCC implemented a combination of same-day and two-day chemotherapy treatments that is consistent with the other BCCA radiation cancer centres. The majority of patients will receive two-day treatments. This reduces waiting times for patients, allows effective use of resources, reduces stresses on clinic staff to meet time lines, and allows both pharmacy and chemotherapy treatment staff more lead time to prepare for treatments. Same day treatments may be requested for frail and elderly patients, patients with travel times of more than one hour, and patients receiving multiple day treatments.

An [index](#) to the orders can be obtained by Fax-back.

DRUG UPDATE

Amifostine (Ethyol™) was withdrawn from the Canadian market in September but is available through Health Canada's Special Access Program.

Amifostine is on the BCCA Benefit Drug List for pediatric patients.

EMLA™ (Eutectic Mixture of Local Anesthetics) no longer requires a prescription and can be purchased in the self-selection area of pharmacies.

Zoledronic Acid or **zoledronate** (Zometa™, Novartis) is a new bisphosphonate approved by Health Canada for the treatment of tumour-induced hypercalcemia following adequate saline rehydration. Zoledronic acid is not currently on the BCCA Benefit Drug List.

Editorial Review Board

Robin O'Brien, PharmD (Acting Editor)

Sharon Allan, MD
 Sandi Broughton, BA(Econ), MSc
 Jack Chritchley, MD
 Linda Yearwood, MSN
 Lynne Nakashima, PharmD
 David Noble, BSc, BLS
 Lynn Stevenson, RN
 Kelly Uyeno, CGA

Gigi Concon (Secretary)

IN TOUCH	http://www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC Cancer Agency	(604)-877-6000	Toll-Free 1-(800)-663-3333
Communities Oncology Network	Ext 2744	bfiddler@bccancer.bc.ca
Nursing Professional Practice	Ext 2623	ilundie@bccancer.bc.ca
Pharmacy Professional Practice	Ext 2247	gconcon@bccancer.bc.ca
Provincial Systemic Therapy Program	Ext 2247	gconcon@bccancer.bc.ca
Communities Oncology Network Pharmacist	Ext 2515	mfung@bccancer.bc.ca
Drug Information	Ext 3028	robrien@bccancer.bc.ca
Library / Cancer Information	Ext 2690	dnoble@bccancer.bc.ca
Update Editor	Ext 3028	robrien@bccancer.bc.ca
Cancer Centre for the Southern Interior (CCSI)	(250) 712-3900	Toll-Free 1-(888)-563-7773
Fraser Valley Cancer Centre (FVCC)	(604)-930-2098	
Vancouver Cancer Centre (VCC)	(604)-877-6000	Toll-Free 1-(800)-663-3333
Vancouver Island Cancer Centre (VICC)	(250) 370-8228	Toll-Free 1-(800)-670-3322

REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES	LOCATION
Pre-Printed Orders	H:\everyone\systemic\chemo\Orders\VCC
Index of Pre-Printed Orders	Index.doc
	GOCXADV
	LYHDMTX
	LYODBEP
Protocol Summaries	H:\everyone\systemic\chemo\Protocol\tumour site"
	CMLIFNCYT GOCXADV
	CNIME GOTDLR
	CNTEMOZ LUDOC
	GIIRFUFA MYMP
Index of Protocol Summaries	Index_NT or Index_W6
Reimbursement	H:\everyone\systemic\chemo\Reimburs
Benefit Drug List (01 November 2000)	BenefitList.doc
Class 2 Form (01 November 2000)	Class2.doc
Systemic Therapy Update Index	H:\everyone\systemic\chemo\Update\2000\Index
	Jan-Dec_NT.doc

For easy access, click on the systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca

BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

FAX (604) 877-0585

bulletin@bccancer.bc.ca

TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES

I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

E-mail (Word 6.0)

Fax

@	
()	Attn:

UPDATES Please Fax-Back information below:

<input type="checkbox"/> All items	
Pre-Printed Orders:	
<input type="checkbox"/> GOCXADV	<input type="checkbox"/> LYODBEP
<input type="checkbox"/> LYHDMTX	<input type="checkbox"/> Index: Pre-Printed Orders
Protocol Summaries:	
<input type="checkbox"/> CMLIFNCYT	<input type="checkbox"/> GOCXADV
<input type="checkbox"/> CNIME	<input type="checkbox"/> GOTDLR
<input type="checkbox"/> CNTEMOZ	<input type="checkbox"/> LUDOC
<input type="checkbox"/> GIIRFUFA	<input type="checkbox"/> MYMP
	<input type="checkbox"/> Index: Protocol Summaries (current month)
Reimbursement	
<input type="checkbox"/> Benefit Drug List (01 November 2000)	
<input type="checkbox"/> Class 2 Form (01 November 2000)	
Systemic Therapy Update Index	
<input type="checkbox"/> Jan-Dec 2000	